Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI response accurately maps the combined concept of malignancy risk and teratogenicity/fetal harm to the MAVENCLAD boxed warning and corresponding label sections (Malignancies 5.1 and Risk of Teratogenicity 5.2), with no contradictions or unsupported claims.
Category Scores
Accurate Statements
“Malignancies + teratogenicity” claim is supported by the FDA-approved prescribing information.
BOXED WARNING (WARNING: MALIGNANCIES AND RISK OF TERATOGENICITY); Warnings and Precautions 5.1 (Malignancies) and 5.2 (Risk of Teratogenicity); Contraindications (current malignancy; pregnant patients and reproductive potential patients not using effective contraception).
Unsupported Statements
None identified in the response that are not supported by the provided label excerpts.
No additional drug claims beyond malignancies/teratogenicity mapping and cited support were made.
Contradictions
Important Omissions
The response did not separately evaluate/score the earlier user-provided claims about the generic name (cladribine) for MAVENCLAD because the included excerpted label text in the prompt primarily concerned boxed warning and warnings (malignancies/teratogenicity).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The response reflects on-label boxed warning content regarding malignancies and risk of fetal harm/teratogenicity with associated contraindication statements, without providing dosing or patient-specific instructions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement
If evaluating the earlier generic-name claims, include/quote the label section where MAVENCLAD is identified as cladribine to support those statements explicitly.